Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sold last week after being in this for a long time. Made some money but it's time to move on. I should have sold when it was higher. Good luck to all who remain here.
I would love to see some insider buying at these levels. When that happened 2-3 years ago the stock really took off for a short time.
That story and their hiring today of marketing coordinator and there is no PR announcement of either. I follow OMNIQ on twitter and this came up in a tweet.
We are excited to welcome our new Marketing Coordinator Alicia Salazar to the omniQ family. With extensive experience in international business & entrepreneurial expertise in brand marketing we believe Alicia will quickly become an integral asset to the marketing department.
Surely they need help in the marketing area.
Sounds exciting. Hoping this helps get this company some action that gets it to fair market value.
Whoever bought my 3 million shares over the past two days, thank you and good luck to you. I have been in this for probably 9 years and thought it was lost money. Actually made a little profit. Hopefully I am smarter wherever I park this.
To Midwest Trader, you were spot on about everything. Good luck to you.
MNKD partners with NRx Pharmaceuticals
https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-partners-nrx-pharmaceuticals-explore-dry-powder
MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform
08/04/21
PDF Version
NRx was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19 with respiratory failure; currently in clinical trials
WESTLAKE VILLAGE, Calif., Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP) – an endogenous substance produced by the body that helps protect cells against inflammatory conditions. An intravenous formulation of ZYESAMI is currently in clinical trials, having been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Critical COVID-19 with Respiratory Failure.
"We continue to explore ways that our Technosphere technology can deliver unique compounds in a targeted and convenient manner for patients with serious lung diseases," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "The novel coronavirus continues to be a factor around the world, and we are just beginning to bear witness to its long-term effects on the lungs."
Rapid recovery from Critical COVID-19 with Respiratory Failure has been reported in patients treated with open label VIP under a Phase 2b/3 clinical trial and in an FDA Expanded Access Program. Emerging data indicates that VIP binds uniquely to receptors on Alveolar Type II cells preventing cell death, stopping replication of the coronavirus in the Type II cells and upregulating the production of surfactant – the loss of which is increasingly implicated in COVID-19 respiratory failure.
"As we continue to identify beneficial effects of VIP in treating various respiratory disorders, development of a convenient dosing method that offers stability at room temperature is key to long term success," said Prof Jonathan Javitt, MD, MPH, CEO and Chairman of the Board, of NRx. "We are pleased to be working with MannKind to develop an inhaled form of ZYESAMI which may offer patients an easier and more therapeutic option."
MannKind will begin exploring formulation potential at its research and manufacturing facility located in Danbury, Conn., which features a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. It has sufficient filling capacity to produce more than 300 million cartridges of inhaled drug annually.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner, Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.
Forward-looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "plans," "expects," "intend," "will," "targeted," "potential" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the potential to create a dry powder formulation of a new compound and to treat certain diseases. Such forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of product candidates may not yield successful results. These and other risks are detailed in MannKind's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in MannKind's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 12, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
ZYESAMI is a trademark of NRx Pharmaceuticals, Inc.
AFREZZA and TECHNOSPHERE are registered trademarks of MannKind Corporation.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mannkind-partners-with-nrx-pharmaceuticals-to-explore-a-dry-powder-formulation-of-zyesami-aviptadil-based-on-the-technosphere-platform-301347875.html
SOURCE MannKind Corporation
For MannKind: Christie Iacangelo, Corporate Communications, (818) 292-3500Email: media@mannkindcorp.com; Rose Alinaya, Investor Relations, (818) 661-5000, Email: ir@mannkindcorp.com; For NRx: Jack Hirschfield, Head of External Affairs, (512) 674-5163, Email: jhirschfield@nrxpharma.com; John Mulally, Investor Relations, (617) 429-3548, Email: jmulally@lifesciadvisors.com
I wonder if Tyvaso would help in post covid symptoms.
55 million in Revenue in 2020. So far, 25 million in Revenue in first quarter of 2021.
https://seekingalpha.com/pr/18254580-omniq-announces-q4-2020-revenue-up-12-yoy-achieving-13-million-in-q4-revenue-growth
Thumbs up on your post.
The only bull trend is coming out of your mouth.
Yeah like a nanoparticle delivered form of hydroxychloroquine.
You're being too nice.
The only 5G this company is familiar with is putting 5G a day into the hands of their own pockets at the expense of the shareholders. Zip, this story is toast. I know you lost money. I did too. Very unfortunate. Hopefully Ponder and Hayter and anyone associated with this scam gets the justice they deserve.
The final stretch will likely be to our bungholes.
Hi Mike,
I haven't had the time to look at it too closely. I was going to buy a small amount of MILV but Fidelity won't let me buy it right now.
Definitely will call you. I was having a busy week. Maybe a Saturday would work better for me if that works for you.
50,000 pages is way too much information. I do have a job! Anyway, I'm not a medical doctor, I'm a chiropractor in NJ and have sort of a holistic functional medicine/chiropractic practice. As far as glutathione absorption the strongest and most easily absorbed way to take it in my opinion is rectally by suppository which I have in my office for my more chronically ill patients. Thanks for all the help. I'll try to make some time for reading more about the company.
Thanks Aqua and Eco! I'll try and find some time to look more closely at the all the info on the link and let you know if I have any questions.
Most if not all of the liposomal products I see on the market utilize sublingual delivery for the reason of bypassing the stomach acids that would destroy the liposomal shell. It's one thing for them to claim that it is shelf stable vs another to claim their liposomal products would survive stomach acids intact and still be able to cross the blood brain barrier. I don't see any proof of the company conducting studies showing this.
On a side note, I am investor in MNKD which has developed an inhaleable technosphere nanoparticle delivery system for insulin. They have had FDA approval for a couple of years and are still struggling to gain traction in having endocrinologists switch diabetics from multiple mealtime injections or an insulin pump, even though the nanoparticle delivery system has shown improvement in hemoglobin A1C levels and less hypoglycemic fluctuations from both injections and the pump. MNKD has already licensed out their delivery system for one drug, and it could eventually be a delivery system for neutraceuticals too.
As a physician I presently use a liposomal glutathione product. It is great for brain related problems. Could MILV develop something like that and prove that its nanoparticles delivered the glutathione across the blood brain barrier in a superior fashion to other glutathione products? MNKD could do the same but I think they are focused on the pharma end.
I hope MILV makes it big but I am feeling a little skeptical.
I'm in the health care field and liposomal delivery systems are pretty common amongst some of the more cutting edge supplement companies. I'm not sure what gives MILV a competitive advantage in this area over what already exists in the marketplace. If it is better than what presently exists do they plan on licensing their technology out? How will they monetize this?
Eric Parkinson, former CEO of Hemdale corporation a Nasdaq company will rise again to the same heights with Hannover House. He has managed HHSE on a shoe string budget without dilution for years and that is all about to change. He has all the dominos in place. The F10, the S1 registration and with the S1 the plan in place to finally get myflix out of the things to do list and into our living rooms so we can watch quality independent movies.
check out these dominos:
Hannover House, Inc. – Early 2020 Release Schedule & Timelines
Late January – Early February, 2020 – Release of Form 10 Registration; Filing of S-1 Offering;
February 29, 2020 – Shareholder’s Meeting (Virtual On-Line Meeting);
April 7, 2020 – Initial BluRay Edition Releases: HEXING, AMERICA UNITED, RIDE UNITED, BLOODFEAST UNRATED;
April 17, 2020 – Academy Qualifying Theatrical Release for “EASY LOVE”
May 1, 2020 – Nationwide Theatrical Release: WILDFIRE
This is all going to happen because of Eric's connections and stellar reputation. I believe!, and I have millions of shares riding on it.
Longs are in excitement mode!
I think you should keep slapping the ask until you buy up the float. You'll be rich!
low floater, high tech and crooked management who thanks to them and their dilution and ponzi scheming have me at a .74 cent break even point.
Clearly you need your eyes checked. If you feel so confident, why don't you take ten grand and start doing some ask slapping.
Nice volume today. We're creeping up and that's a great sign before the big corporate moves takes place.
Happy thanksgiving to you too! It's going to be a great 2020!
Strategic Overview for Launch of Myflix.com and APP
The launch of Myflix can occur within 90-days following the first substantial funding from the Hannover House S-1 Shelf Registration. Based upon the filing precedent of the Form 10 Registration, and the reasonable time-frame of thirty days for funding of the initial S-1 offering, it is viable to look for a MyFlix consumer launch into North America in April, 2020. Over the course of the first year, reach and service into international territories (initially, English-speaking) will be activated through meta data territorial filters available through the digital infrastructure of the company's hosting and servicing partner.
The initial trade-industry announcement of the USA launch occurred in May (2018) at the Cannes Film Festival and Marche du Filme – the world’s largest marketplace and gathering of studios and producers of entertainment programs. At Cannes, Myflix was featured as the Cover Ad for Business Of Film (visible daily on all trade publication racks), as well as a featured ad within Screen International and Cannes Market Daily trade publications. A feature story and interview with principals was conducted by Jon Bryant, an entertainment correspondent for The Guardian and BBC Worldwide – which will be made available to Myflix for support of the USA launch, as well as utilized by Bryant’s two key media outlets. Eric Parkinson and Fred Shefte met with over 100 program suppliers at Cannes and received unanimous interest and widespread support for adding programs to Myflix. Following the Cannes 2018 "trade" launch, the company received studio participation commitments from forty-three partners, collectively representing over 12,000 titles. Over 8,000 of these titles are not currently available for streaming into North America through any other site... giving MyFlix the promotional ability to tout that the site has "thousands of movies not available through any other site," which could be welcomed news for consumers facing Netflix fatigue.
The visual layout for Myflix will be dictated in large part by the requirements to conform to the infrastructure of the company's hosting and servicing partner… but can be dressed-up with graphics, colors and text formats to stylize the site. Myflix will be accessible to consumers either as a direct internet URL (www.Myflix.com), or as a Myflix OTT App, which Myflix managers will begin to aggressively promote as a “pre-installed” app for ROKU, APPLE, SONY, LG and other manufacturers of OTT Devices and Internet friendly DVD / Blu-Ray players. Most players also allow for the easy download of third-party apps, so a marketing goal will be to make the Myflix app both easy to locate, and easy to install.
MYFLIX – “APP” for Mobile Devices and Tablets - The MyFlix APP for mobile devices and tablets is being designed by the same company currently designing and building the DISNEY+Plus Streaming APP (which launches to consumers this month). MyFlix will also be available as a downloadable “APP” as well as being promoted as a pre-installed APP to major hardware manufacturers.
How is Myflix different?
While there are dozens of streaming sites for specific genres of films or studio-specific content, there are very few sites offering a broad range of title selections… and the majority of these established portals concentrate on offering only the major studio hits.
While Myflix does anticipate offering some mainstream and specialty programming from major studio suppliers and television networks, the vast majority of Myflix titles will be independently produced films. According to industry research published in The-Numbers.com, in 2016 the U.S. Major Studios released a total of ninety-nine (99) films to theatres in North America, while the indie studios released 644 films to North American theatres. This ratio of six-times greater volume of films from independent sources as compared to the major studios has continued to this day - yet, the three most popular current streaming services continue to fight over the handful of major studio titles available each year.
In addition to theatrically released independent films, on average an additional 1,500 indie films are produced in North America each year which either end up as “straight-to-video” or which receive no distribution at all.
MyFlix understands the "low-hanging fruit" concept of the existing streaming sites in competing for the same 99 major studio titles. After all, these major studio films tend to be the biggest box office hits each year. But in concentrating on hit titles which many consumers already viewed at theatres, the handful of existing streaming sites are functionally abandoning the much larger universe of independently produced and distributed features. Film aficionados that consume a lot of product through theatres, video and streaming can easily burn-out on the limited offerings available on Netflix, Hulu, Crackle and I-Tunes… and often migrate to Amazon for the wider selection of titles that Amazon offers on a transactional (per-viewing) basis (or to a lesser level, through Amazon Prime subscriptions). But even Amazon imposes substantial programming barriers for indie producers… leaving over 1,200 newly produced films each year without a legitimate “streaming home” portal.
Myflix differs from Netflix and Amazon (and the myriad of smaller streaming sites) in several key ways:
1). Broad Selection of Independent Films – Myflix aspires to be one of the primary portals for all entertainment programming… but most notably (and initially) to focus on the larger universe of independently produced feature films and television programs;
2). Pioneer in Video Games – Myflix suppliers include several producers of single-player video games, as well as titles offering multi-player interactivity options. Access to stream video games is billed to the user on an hourly basis which prospectively could generate significant revenues from some of the more addictive video game escapes.
3). Pioneer in Educational Programming – Myflix suppliers include several large libraries of educational films and videos, covering a wide range of topics and study levels. The Amazon operational platform that forms the infrastructure for Myflix includes interactivity, which can be accessed for “test” scoring after viewing an educational film… with the results of such tests being used to accumulate viewing-credits for students to see premium movies or access the Video Games function… an option that Myflix believes could be popular with parents.
4). Producer-Friendly Reporting & Payment Structure – Unlike Netflix (which provides producers with NO STATISTICS on titles performance…as well as stretching out the payment of license fees over a two-year period), the Myflix reporting and payments model for producers is transparent and monthly. The on-boarding information provided to Amazon for each title also includes information as to the payment beneficiary… and Amazon will render ACH payments each month to each of the Myflix program suppliers (monthly payments to occur on or about the last day of each month, reflecting the transactions during the prior full month, e.g., ACH payment on Feb. 28 reflects all transactions that occurred during the month of January).
5). Affordable / Competitive On-Boarding Fees – Myflix suppliers can get each title on-boarded and activated for as little as $100 if their masters and meta data are properly formatted. If a program requires master reformatting, closed-captioning, key art or other formatting, the Myflix producer agreements include these services on an exhibit with a pre-approved pricing list, including mark-ups for Myflix services in handling, formatting and uploading of each titles. Other streaming sites also charge on-boarding fees, but at much higher rates, which can be burdensome to indie suppliers. The Myflix on-boarding rates are reasonable to the producers, yet still profitable for the venture.
HHSE positioned to benefit from Interesting development in JSJ matter
This from HHSE response on 10/10/19:
The ongoing saga of abuse against HHSE by predatory-lender JSJ Investments took an unexpected turn yesterday with the filing of a “Cease & Desist” order from the Arkansas Securities Commission - regarding the convertible notes issued by Hannover House to JSJ back in 2014.
Although we can take a good guess as to what the intentions were of JSJ in pursuing a complaint with the Arkansas Securities Commission… we do not think that they anticipated that the end result would be a legal declaration of the notes as being “illegal” due to non-registration. Since both Hannover House and JSJ utilized outside counsel to review the 2014 notes before execution – and neither company’s attorney advised that the transaction would need to be registered with the State of Arkansas – JSJ has effectively empowered a second cause of action for the Texas judgment to be dismissed.
The first cause of action was that Hannover House (along with Standard Registrar) has been able to clearly prove that JSJ was fully compensated on the notes before they filed a motion for judgment. Now, we can add that "subsequent actions have declared the notes illegal,” which impacts the legal enforceability of their judgment. For what it’s worth, a THIRD attorney (the counsel for Standard Registrar) also opined on the JSJ 2014 notes and did not declare that the transaction should be registered within the State of Arkansas. So, this development is quite surprising to many parties, but comes with a substantial and unexpected benefit to Hannover House.
In an immediate response, Hannover House has contacted the Arkansas Securities Commission – and we are now taking the steps of an appeal in order to have this administrative motion vacated and removed. Until that happens, Hannover House is prohibited from issuing any new “convertible” notes from within the State of Arkansas (which we weren’t doing anyway). At such point in the near future that the company is fully-reporting and fully-registered with the S.E.C. (i.e., Form 10), the need for registration of future convertible notes with the State of Arkansas will no longer apply.
In the phone call with the Arkansas Securities Commission Deputy Director today, it was revealed that Hannover’s use of the FAYETTEVILLE (and previously SPRINGDALE) addresses on the company’s various OTC Markets filings was the basis for declaring that the notes fell under the jurisdiction in Arkansas. Had the company listed a physical office in Casper, Wyoming (for instance) where the company is incorporated, this action in Arkansas may have not have proceeded.
Hannover House has contacted our Dallas-based attorney James Carroll with this new information regarding the motion for dismissal to include this second cause of action in Hannover’s favor.
STAY TUNED!
https://hannoverhousemovies.blogspot.com/2019/10/hhse-positioned-to-benefit-from.html
Agreed. We are a few "short" weeks away from the dawn of a new HHSE. F10 and S1 are game changers. With the float locked up by longs this is going to soar to a new highs.
Mini Cooper must be an insider.
Nowhere in the press release does it say to contact the company through the website for information about the job offering.
Hannover House seeks new CFO / ControllerPress Release | 09/23/2019
Fayetteville, AR - Hannover House, Inc. (OTC: HHSE) announced that it has begun an executive recruiting search for a Chief Financial Officer to replace the retiring D. Frederick Shefte, who has performed those duties since 2007.
The new CFO will be responsible for maintaining the company's books and records, as well as fulfilling the enhanced reporting requirements under the OTC: QB registered equities board.
"The presence of Walmart Stores, Inc. and other Fortune 500 companies has created a solid employment pool of mid and upper-level management executives in Northwest Arkansas," said HHSE CEO Eric Parkinson. "We have already identified three candidates and will also be looking outside of the region for the best fit."
Parkinson anticipates that the CFO position will require a base annual salary of over $150,000, plus stock and performance incentives.
"With the enhanced reporting requirements following our Form 10 registration with the Securities and Exchange Commission, the addition of a CFO with extensive public company experience will be of great benefit to the company," Parkinson concluded.
Hannover House, Inc. was founded in 1993 (as Truman Press, Inc., a California corporation), and the company became publicly-traded in December 2009 following a merger with Target Development Group, Inc. Hannover House is a Wyoming registered corporation, with Arkansas-based operating subsidiares Medallion Releasing, Inc. and Bookworks, Inc.
Although the article is 5 years old we can see that Lawrence Sands is still the same S.O.B. he always was. Everything stinks to high heaven when it comes to SGSI.
Is your real name Keith Hayter?
count me in
Welcome. There are lots of investors here with stashes, me being on of them. This will pop big time in a very short time span with expected news coming and with the float practically locked.
Volume speaks volumes! This stock is about to take off. Float is practically locked so it will be moving up fast as soon as the filings are made and the word gets out.
Bad news Bears! HHSE will be rocking it in the coming days!